Callan Capital LLC Invests $209,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Callan Capital LLC purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,982 shares of the medical equipment provider’s stock, valued at approximately $209,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its position in Zimmer Biomet by 165.3% during the third quarter. Blue Trust Inc. now owns 1,719 shares of the medical equipment provider’s stock worth $187,000 after purchasing an additional 1,071 shares during the period. International Assets Investment Management LLC boosted its position in shares of Zimmer Biomet by 19,988.0% during the 3rd quarter. International Assets Investment Management LLC now owns 107,471 shares of the medical equipment provider’s stock worth $11,601,000 after acquiring an additional 106,936 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Zimmer Biomet by 15.9% in the third quarter. Assenagon Asset Management S.A. now owns 28,145 shares of the medical equipment provider’s stock valued at $3,038,000 after acquiring an additional 3,859 shares during the last quarter. Tectonic Advisors LLC raised its position in Zimmer Biomet by 20.8% during the third quarter. Tectonic Advisors LLC now owns 3,647 shares of the medical equipment provider’s stock valued at $394,000 after purchasing an additional 629 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Zimmer Biomet by 26.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,511 shares of the medical equipment provider’s stock worth $1,895,000 after purchasing an additional 3,633 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 1.2 %

Shares of NYSE ZBH opened at $104.89 on Monday. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The company’s 50 day moving average price is $105.86 and its 200-day moving average price is $107.46. The company has a market capitalization of $20.88 billion, a P/E ratio of 23.57, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the business earned $2.20 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.92%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Raymond James decreased their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Truist Financial reissued a “hold” rating and set a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Stifel Nicolaus raised their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Barclays lowered their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Finally, Royal Bank of Canada decreased their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.